Skip to main content
Debashis Sarker

Dr Debashis Sarker

Clinical Reader in Experimental Oncology

Research interests

  • Cancer

Biography

Debashis Sarker is Reader in Experimental Oncology within the Comprehensive Cancer Centre and Consultant Medical Oncologist at Guy's, St Thomas' and King's College Hospitals. His main research interests are in first-in-human development of novel molecularly targeted agents, molecular and cellular immunotherapies and is the co-lead of King’s Health Partners Experimental Cancer Medicine Centre. He specialises in management of liver, pancreatic and neuroendocrine cancers with a particular focus in developmental therapeutics and genomics. He is the clinical co-lead at NHSE South East Genomic Medicine Service and Laboratory Hub and is the Deputy Director of NIHR Guy’s and St Thomas Clinical Research Facility.

    Research

    GI cancer programme 780x440
    Programme in Gastrointestinal Cancer

    The Programme in GI Cancer focuses on GI tract diseases, mostly cancer and oesophago-gastric cancer. This group spans a broad field of interests, promoting collaborative working within KCL, nationally and internationally.

    Novel immunotherapy 780x440
    Cancer Early Phase Trials Unit

    Led by Professor James Spicer, Dr Debashis Sarker and Dr Rebecca Kristeleit, the Cancer Early Phase Trials Unit focuses on the discovery and development of novel molecular and cellular cancer immunotherapies.

    experimental-oncology
    Experimental Oncology

    The Experimental Oncology Programme is focused on the development of new treatments for solid tumours.

    Project status: Ongoing

    Hepatobiliary thumbnail
    Hepatobiliary neoplasms

    King’s College Hospital hosts one of Europe’s largest hepato-pancreato-biliary cancer clinical services.

    News

    COVID reforms in cancer care and research could have long-term benefits

    A new review led by Professor James Spicer considers the reforms in cancer care and research made due to the pandemic, arguing that some have left a positive...

    cancer care post covid 780×450

    Experimental cancer treatments receive funding boost

    King's Health Partners (KHP) Experimental Cancer Medicine Centre (ECMC) has had its funding renewed for the next five years.

    Cancer globally

      Research

      GI cancer programme 780x440
      Programme in Gastrointestinal Cancer

      The Programme in GI Cancer focuses on GI tract diseases, mostly cancer and oesophago-gastric cancer. This group spans a broad field of interests, promoting collaborative working within KCL, nationally and internationally.

      Novel immunotherapy 780x440
      Cancer Early Phase Trials Unit

      Led by Professor James Spicer, Dr Debashis Sarker and Dr Rebecca Kristeleit, the Cancer Early Phase Trials Unit focuses on the discovery and development of novel molecular and cellular cancer immunotherapies.

      experimental-oncology
      Experimental Oncology

      The Experimental Oncology Programme is focused on the development of new treatments for solid tumours.

      Project status: Ongoing

      Hepatobiliary thumbnail
      Hepatobiliary neoplasms

      King’s College Hospital hosts one of Europe’s largest hepato-pancreato-biliary cancer clinical services.

      News

      COVID reforms in cancer care and research could have long-term benefits

      A new review led by Professor James Spicer considers the reforms in cancer care and research made due to the pandemic, arguing that some have left a positive...

      cancer care post covid 780×450

      Experimental cancer treatments receive funding boost

      King's Health Partners (KHP) Experimental Cancer Medicine Centre (ECMC) has had its funding renewed for the next five years.

      Cancer globally